Upstream Bio Receivables 2024-2025 | UPB

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Upstream Bio receivables from 2024 to 2025. Receivables can be defined as the total amount of collectibles for a company

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Upstream Bio receivables from 2024 to 2025. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$247.8B
Amgen (AMGN)	$154.9B
Gilead Sciences (GILD)	$140.2B
Vertex Pharmaceuticals (VRTX)	$100.3B
Bristol Myers Squibb (BMY)	$96B
GSK (GSK)	$80.8B
CSL (CSLLY)	$67.1B
Regeneron Pharmaceuticals (REGN)	$61.5B
Alnylam Pharmaceuticals (ALNY)	$58.5B
Argenex SE (ARGX)	$43.6B
Insmed (INSM)	$28.8B
BioNTech SE (BNTX)	$24B
Royalty Pharma (RPRX)	$21B
Biogen (BIIB)	$19.4B
Incyte (INCY)	$16.5B
Genmab (GNMSF)	$16.5B
Genmab (GMAB)	$16B
Illumina (ILMN)	$15.4B
Ascendis Pharma (ASND)	$11.9B
BioMarin Pharmaceutical (BMRN)	$11.2B
Swedish Orphan Biovitrum (BIOVF)	$10.9B
QIAGEN (QGEN)	$10.3B
Exelixis (EXEL)	$10.1B
Moderna (MRNA)	$9.4B
Verona Pharma American Depositary Share (VRNA)	$9.2B
Exact Sciences (EXAS)	$9B
Bio-Techne Corp (TECH)	$8.6B
Halozyme Therapeutics (HALO)	$8.6B
Guardant Health (GH)	$8.4B
Blueprint Medicines (BPMC)	$8.3B